Skip to Content

Drug interactions between Pepto-Bismol and Tasigna

Results for the following 2 drugs:
Pepto-Bismol (bismuth subsalicylate)
Tasigna (nilotinib)

Interactions between your drugs

There were no interactions found in our database between Pepto-Bismol and Tasigna. However, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Pepto-Bismol

A total of 253 drugs (1325 brand and generic names) are known to interact with Pepto-Bismol.

Tasigna

A total of 1000 drugs (5596 brand and generic names) are known to interact with Tasigna.

Drug and food interactions

Major

nilotinib food

Applies to: Tasigna (nilotinib)

Do not consume grapefruit or grapefruit juice during treatment with nilotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of nilotinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with nilotinib. Food may also increase the blood levels of nilotinib. Therefore, you should take nilotinib on an empty stomach, meaning no food should be eaten for at least two hours before or one hour after taking nilotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide